Detail akcie Futura Medical online

Business Summary: Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Futura Medical PLC revenues increased from L3.1M to L13.9M. Net income totaled L1.3M vs. loss of L6.5M. Revenues reflect EU and UK segment increase of 75% to L4.8M, Rest of the world (Region) segment increase from L375K to L1.3M. Net Income reflects Development and commercialisation segment income totaling L1.2M vs. loss of L7M.